Clenoliximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric(primate/human) |
| Target | CD4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
  (what is this?)(verify) | |
Clenoliximab(INN[1]) is amonoclonal antibodyagainstCD4.It acts as animmunomodulatorand has been investigated for the treatment ofrheumatoid arthritis.[2] The drug is achimericantibody fromMacaca irusandHomo sapiens.[1]
References
[edit]- ^abWorld Health Organization(1997)."International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77"(PDF).WHO Drug Information.11(2): 89. Archived fromthe original(PDF)on June 27, 2004.
- ^Hepburn TW, Totoritis MC, Davis CB (January 2003). "Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis".Rheumatology.42(1): 54–61.doi:10.1093/rheumatology/keg030.PMID12509613.
 | Thismonoclonal antibody–related article is astub.You can help Wikipedia byexpanding it. |
 | Thisantineoplasticorimmunomodulatorydrugarticle is astub.You can help Wikipedia byexpanding it. |